Dr. Cristina P Rodriguez
Claim this profileSeattle Cancer Care Alliance / University of Washington
Area of expertise
Squamous Cell Carcinoma
Cristina P Rodriguez has run 4 trials for Squamous Cell Carcinoma. Some of their research focus areas include:
Head And Neck Cancers
Cristina P Rodriguez has run 3 trials for Head and Neck Cancers. Some of their research focus areas include:
Affiliated Hospitals
Seattle Cancer Care Alliance / University Of Washington
Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University Of Washington
Clinical Trials Cristina P Rodriguez is currently running
Chemotherapy + Radiation Therapy
for Head and Neck Cancer
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Recruiting
1 award
Phase 2 & 3
21 criteria
Trastuzumab Emtansine
for Salivary Gland Cancer
This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-postive salivary gland cancer that has come back (recurrent), that has spread from where it first started (primary site) to other places in the body, or cannot be removed by surgery (unresectable). This trial is also testing how well trastuzumab deruxtecan works in treating patients with HER2-low recurrent or metastatic salivary gland cancer. Trastuzumab is a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by body's immune system. Trastuzumab emtansine contains trastuzumab, linked to a chemotherapy drug called emtansine. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers emtansine to kill them. Trastuzumab deruxtecan is a monoclonal antibody called traztuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors and delivers deruxtecan to kill them. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Trastuzumab emtansine may work better compared to usual treatment of chemotherapy with docetaxel and trastuzumab or trastuzumab deruxtecan in treating patients with recurrent, metastatic or unresectable salivary gland cancer.
Recruiting
1 award
Phase 2
More about Cristina P Rodriguez
Clinical Trial Related
7 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Cristina P Rodriguez has experience with
- Cisplatin
- Nivolumab
- Pembrolizumab
- Docetaxel
- IK-175
- Carboplatin
Breakdown of trials Cristina P Rodriguez has run
Squamous Cell Carcinoma
Head and Neck Cancers
Lung Cancer
Salivary Gland Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Cristina P Rodriguez specialize in?
Cristina P Rodriguez focuses on Squamous Cell Carcinoma and Head and Neck Cancers. In particular, much of their work with Squamous Cell Carcinoma has involved Stage IV patients, or patients who are p16 negative.
Is Cristina P Rodriguez currently recruiting for clinical trials?
Yes, Cristina P Rodriguez is currently recruiting for 2 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Cristina P Rodriguez has studied deeply?
Yes, Cristina P Rodriguez has studied treatments such as Cisplatin, Nivolumab, Pembrolizumab.
What is the best way to schedule an appointment with Cristina P Rodriguez?
Apply for one of the trials that Cristina P Rodriguez is conducting.
What is the office address of Cristina P Rodriguez?
The office of Cristina P Rodriguez is located at: Seattle Cancer Care Alliance / University of Washington, Seattle, Washington 98109 United States. This is the address for their practice at the Seattle Cancer Care Alliance / University of Washington.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.